Abstract 1960P
Background
Bone and soft tissue sarcomas are uncommon neoplasms that rarely metastasize to the brain. Alveolar soft tissue sarcomas (ASPS) have been reported to have a higher propensity to develop brain metastasis (BM) than other sarcomas. Our study aimed to retrospectively scrutinize the clinical outcome of BM in ASPS.
Methods
35 patients diagnosed with ASPS between 2006 and 2021 were identified from our database. We evaluated the presence or absence of BM, age at diagnosis, gender, primary lesion site, tumor size, other distant metastases at diagnosis, and prognosis. We compared these clinical characteristics between patients with BM and those without BM (nBM). In the BM group, we also assessed symptoms, duration between diagnosis and BM, treatment for BM, and outcomes.
Results
Fifteen patients (43%) exhibited BM. We observed no significant difference in age at diagnosis, gender, primary lesion site, tumor size, or other distant metastases at diagnosis or median overall survival, compared to the nBM group. Seven cases were asymptomatic when BM was diagnosed. Most symptoms were headache and visual disturbance. The mean duration between diagnosis and BM was 46 months (range: 0-189). BM treatment consisted of gamma-knife radiosurgery in 10 cases, multi-targeted kinase inhibitors (TKI) (pazopanib and/or sunitinib) in eight cases, surgery in three cases, and whole-brain irradiation in three cases. After receiving sunitinib treatment, two patients developed brain hemorrhages. The survival after BM was 33 months (range: 0.5-104).
Conclusions
Approximately half of the ASPS cases included in our study developed BM, with 47% of ASPS patients being asymptomatic at the time of BM detection. Periodic imaging, including the head region, may be advisable. Our analysis did not identify specific clinical features that predict BM in ASPS patients. Selective irradiation and chemotherapy have recently emerged as potential therapeutic options for treating BM in ASPS. These advances may contribute to improved prognosis after BM. However, potential serious adverse events associated with these treatments should be carefully considered. In particular, patients receiving TKI therapy may be at risk for brain hemorrhages and should be closely monitored and managed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
E. Kobayashi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1959P - Clinicopathological features and survival analysis of orbital rhabdomyosarcoma
Presenter: Fatma Elawady
Session: Poster session 15
1961P - Prevalence of diagnostic discrepancies in soft tissue and bone tumors from initial diagnosis to referral center
Presenter: Khomsit Thongthammachat
Session: Poster session 15
1963P - Comprehensive profiling of chordoma reveals tumor microenvironment subtypes and unique molecular findings
Presenter: Marina Voropaeva
Session: Poster session 15
1964P - Biomimetics of three-dimensional (3D) osteosarcoma (OS) models: A scoping review
Presenter: Vinesh Sandhu
Session: Poster session 15
1965P - Transcriptional analysis of immune microenvironment of chordomas of the skull base and mobile spine
Presenter: Jason Roszik
Session: Poster session 15
1966P - Extending the interval of denosumab treatment for unresectable giant cell tumor of bone
Presenter: Toshiyuki Kunisada
Session: Poster session 15
1967P - A single-arm multicenter trial of the combination of anlotinib with chemotherapy in patients with stage IIb classic osteosarcoma of the extremity
Presenter: Fan Tang
Session: Poster session 15
1968P - Metastatic Ewing sarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: coline ducrot
Session: Poster session 15
1969P - Intratumoral immune infiltrates in chondrosarcoma (ChS)
Presenter: Piotr Rutkowski
Session: Poster session 15
1970P - Metastatic chondrosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: coline ducrot
Session: Poster session 15